Last reviewed · How we verify
Bimatoprost Sustained Release Implant
Bimatoprost Sustained Release Implant is a Prostaglandin analog Small molecule drug developed by AbbVie. It is currently in Phase 2 development for Treatment of glaucoma. Also known as: AGN-192024, Durysta.
Bimatoprost Sustained Release Implant works by releasing bimatoprost, a prostaglandin analog, to lower intraocular pressure.
Bimatoprost Sustained Release Implant works by releasing bimatoprost, a prostaglandin analog, to lower intraocular pressure. Used for Treatment of glaucoma.
At a glance
| Generic name | Bimatoprost Sustained Release Implant |
|---|---|
| Also known as | AGN-192024, Durysta |
| Sponsor | AbbVie |
| Drug class | Prostaglandin analog |
| Target | FP receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
Bimatoprost is a selective FP receptor agonist that reduces aqueous humor production, leading to decreased intraocular pressure. This sustained release implant provides a long-term solution for glaucoma treatment.
Approved indications
- Treatment of glaucoma
Common side effects
- Conjunctival hyperemia
Key clinical trials
- Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma (NA)
- Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
- Expanded Access to Bimatoprost (Durysta)
- Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
- A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bimatoprost Sustained Release Implant CI brief — competitive landscape report
- Bimatoprost Sustained Release Implant updates RSS · CI watch RSS
- AbbVie portfolio CI
Frequently asked questions about Bimatoprost Sustained Release Implant
What is Bimatoprost Sustained Release Implant?
How does Bimatoprost Sustained Release Implant work?
What is Bimatoprost Sustained Release Implant used for?
Who makes Bimatoprost Sustained Release Implant?
Is Bimatoprost Sustained Release Implant also known as anything else?
What drug class is Bimatoprost Sustained Release Implant in?
What development phase is Bimatoprost Sustained Release Implant in?
What are the side effects of Bimatoprost Sustained Release Implant?
What does Bimatoprost Sustained Release Implant target?
Related
- Drug class: All Prostaglandin analog drugs
- Target: All drugs targeting FP receptor
- Manufacturer: AbbVie — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of glaucoma
- Also known as: AGN-192024, Durysta
- Compare: Bimatoprost Sustained Release Implant vs similar drugs
- Pricing: Bimatoprost Sustained Release Implant cost, discount & access